Thursday May 25th 2017

Posts Tagged ‘Paolo Zamboni’

MS patients fight for access to new ‘Zamboni’ treatment

MS patients fight for access to new ‘Zamboni’ treatment

A month after Italian vascular surgeon Dr. Paolo Zamboni’s controversial report on treating multiple sclerosis made headlines in November 2009, an elated Jamie Chalmers went to his neurologist and handed him a stack of print-outs on the new findings. Without so much as a [Read More]

Video: Omar Majdi CCSVI Treatment in Bulgaria

Video: Omar Majdi CCSVI Treatment in Bulgaria

Omar’s CCSVI Treatment in Tokuda Hospital, Bulgaria – 11 June 2010 [Read More]

Plight of MS patients exposes flaws in Canada’s approach to medical research

Plight of MS patients exposes flaws in Canada’s approach to medical research

Diana Gordon travelled to the United States earlier this month to have a new MS treatment touted by Italian doctor Paolo Zamboni. After the procedure, which opens up blocked or malformed veins, the Barrie, Ont., woman said she has noticed several improvements in her health, [Read More]

 Page 3 of 10 « 1  2  3  4  5 » ...  Last » 

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]